Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Saul RG"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kaczmarczyk JA; Antibody Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA., Roberts RR; Antibody Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA., Luke BT; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA., Chan KC; Protein Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.; Current address: The Center for Cell Clearance, University of Virginia, Charlottesville, VA 22908, USA., Van Wagoner CM; Protein Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.; Current address: The Center for Cell Clearance, University of Virginia, Charlottesville, VA 22908, USA., Felder RA; Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA., Saul RG; Antibody Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA., Simona C; Antibody Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA., Blonder J; Antibody Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
Publikováno v:
Oncotarget [Oncotarget] 2021 Sep 28; Vol. 12 (20), pp. 2022-2038. Date of Electronic Publication: 2021 Sep 28 (Print Publication: 2021).
Autor:
Schoenherr RM; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Huang D; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Voytovich UJ; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Ivey RG; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Kennedy JJ; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Saul RG; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Colantonio S; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Roberts RR; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Knotts JG; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kaczmarczyk JA; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Perry C; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hewitt SM; National Cancer Institute, Bethesda, MD, USA., Bocik W; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Whiteley GR; Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hiltke T; National Cancer Institute, Bethesda, MD, USA., Boja ES; National Cancer Institute, Bethesda, MD, USA., Rodriguez H; National Cancer Institute, Bethesda, MD, USA., Whiteaker JR; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Paulovich AG; Fred Hutchinson Cancer Research Center, Seattle, WA, USA. apaulovi@fredhutch.org.
Publikováno v:
Scientific data [Sci Data] 2019 Aug 29; Vol. 6 (1), pp. 160. Date of Electronic Publication: 2019 Aug 29.
Autor:
Smith TC; Department of Radiology, Division of Cell Biology & Imaging, University of Massachusetts Medical School, Worcester, MA, United States of America., Saul RG; Antibody Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research ATRF, Frederick, MD, United States of America., Barton ER; Applied Physiology & Kinesiology, College of Health & Human Performance, University of Florida, Gainesville, FL, United States of America., Luna EJ; Department of Radiology, Division of Cell Biology & Imaging, University of Massachusetts Medical School, Worcester, MA, United States of America.
Publikováno v:
PloS one [PLoS One] 2018 Oct 17; Vol. 13 (10), pp. e0205910. Date of Electronic Publication: 2018 Oct 17 (Print Publication: 2018).
Autor:
Navas T; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Pfister TD; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Colantonio S; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Aziz A; Biosciences Division, Argonne National Laboratory, Argonne, Illinois, United States of America., Dieckman L; Biosciences Division, Argonne National Laboratory, Argonne, Illinois, United States of America., Saul RG; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Kaczmarczyk J; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Borgel S; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America., Alcoser SY; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America., Hollingshead MG; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America., Lee YH; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Bottaro DP; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America., Hiltke T; Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, Maryland, United States of America., Whiteley G; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Kinders RJ; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Parchment RE; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America., Tomaszewski JE; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
Publikováno v:
PloS one [PLoS One] 2018 Jun 21; Vol. 13 (6), pp. e0199361. Date of Electronic Publication: 2018 Jun 21 (Print Publication: 2018).
Autor:
Ye X; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Luke BT; Advanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Wei BR; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Kaczmarczyk JA; Cancer Research Technology Program, Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Loncarek J; Laboratory of Protein Dynamics and Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA., Dwyer JE; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Johann DJ; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72209, USA., Saul RG; Cancer Research Technology Program, Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Nissley DV; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., McCormick F; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA., Whiteley GR; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA., Blonder J; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Publikováno v:
Oncotarget [Oncotarget] 2018 May 29; Vol. 9 (41), pp. 26431-26452. Date of Electronic Publication: 2018 May 29 (Print Publication: 2018).
Autor:
Frieling JS; Departments of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Shay G; Departments of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Izumi V; Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Aherne ST; Departments of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Saul RG; Antibody Characterization Lab, Leidos Biomedical Research, Frederick, MD, USA., Budzevich M; Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Koomen J; Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Lynch CC; Departments of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Publikováno v:
Oncogene [Oncogene] 2017 Aug; Vol. 36 (31), pp. 4498-4507. Date of Electronic Publication: 2017 Apr 03.
Autor:
Schoenherr RM; From the ‡Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., P.O. Box 19024, Seattle, Washington 98109-1024;, Saul RG; §Leidos Biochemical Research, Inc., Frederick National Laboratory for Cancer Research ATRF, C1014, 8560 Progress Drive, Frederick, Maryland 21701., Whiteaker JR; From the ‡Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., P.O. Box 19024, Seattle, Washington 98109-1024;, Yan P; From the ‡Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., P.O. Box 19024, Seattle, Washington 98109-1024;, Whiteley GR; §Leidos Biochemical Research, Inc., Frederick National Laboratory for Cancer Research ATRF, C1014, 8560 Progress Drive, Frederick, Maryland 21701., Paulovich AG; From the ‡Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., P.O. Box 19024, Seattle, Washington 98109-1024; apaulovi@fhcrc.org.
Publikováno v:
Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2015 Feb; Vol. 14 (2), pp. 382-98. Date of Electronic Publication: 2014 Dec 15.
Autor:
Whiteley GR; Clinical Proteomics Reference Lab, Advanced Technology Program, SAIC-Frederick, NCI-Frederick, PO Box B, Frederick, MD 21702, USA. WhiteleyG@ncifcrf.gov, Colantonio S, Sacconi A, Saul RG
Publikováno v:
Clinics in laboratory medicine [Clin Lab Med] 2009 Mar; Vol. 29 (1), pp. 57-69.